2023-05-12 08:30:19 ET
- Sosei Group press release ( OTCPK:SOLTF ): Q1 GAAP EPS of -¥17.11.
- Revenue of ¥943M (-15.8% Y/Y).
- Outlook: At present, the Group has a strong cash runway into 2025 to fund its R&D activities. Our cost estimates and key initiatives for 2023 are as follows: Forecast R&D expenses in the range of JPY 8,000 to JPY 10,000 million2 (unchanged).
- Forecast G&A expenses in the range of JPY 4,250 to JPY 4,750 million2 (unchanged).
- We expect to receive upfront payments relating to one or more new partnerships.
- We expect to receive milestone payments as a result of the progress of R&D at existing partners. • We will expand our drug candidate discovery into novel drug targets to enhance our pipeline.
- We expect to start clinical trials of multiple development candidates for which we have rights.
- We will seek out late-stage clinical candidates to in-license and develop for the Japanese market.
For further details see:
Sosei Group GAAP EPS of -¥17.11, revenue of ¥943M